in past times several years, the UK has witnessed a revolution in clinical bodyweight‑loss treatment plans — in the introduction of semaglutide (Wegovy®) towards the escalating reputation of tirzepatide (Mounjaro®). Now, An additional title is drawing focus in both of those medical and community